ReviewInfection & chemotherapy2022
Review in Infection & chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.Mycopathologia · 2024Pooled it
- Oxidative stress-responsive cell wall remodeling depends on phosphate in Candida albicans.Nature communications · 2026Article
- Transfer ofOpen forum infectious diseases · 2026Article
- Clinical Practice Recommendations for the Treatment ofInfection & chemotherapy · 2026Review
- Study Clinical Characteristics and Outcomes ofJournal of clinical medicine · 2026Article
- Beyond intrinsic resistance: novel insights into the emergence and management of resistance acquired in Candida auris upon antifungal exposure.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Clinical implications in patients with isolation of Candidozyma auris in a single tertiary hospital.BMC infectious diseases · 2026Article
- Article
- Infection by Different Clades of Candidozyma auris in a Galleria mellonella Model: Determining Virulence Levels.Mycopathologia · 2026Article
- Recent Outbreaks, Resistance Trends, and Control Measures inJournal of fungi (Basel, Switzerland) · 2026Review
- Isolation and Genomic Profiling of Multi-Drug-Resistant pathogen Candidozyma auris, Including the New Clade VI, Through Wastewater Surveillance in Abu Dhabi, United Arab Emirates.Communications medicine · 2026Article
- Article
- Airborne Fungal Monitoring in Healthcare Environments: A Systematic Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Article
- A Carboxyl-Functionalized Graphene Quantum Dot Coating for Catheters Effective Against Emerging Drug-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Machine learning identifies novel signatures of antifungal drug resistance in Saccharomycotina yeasts.PLoS genetics · 2026Article
- Article
- Fluorescent Probes Derived from the Polyene Class of Antifungal Drugs Reveal Distinct Localization Patterns and Resistance-Associated Vacuolar Sequestration in Candida Species.Angewandte Chemie (International ed. in English) · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.